Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Propanc Biopharma, Inc. amended loan of not changed with same Investor at not changed maturing June 15, 2025 (extended from previous maturity; Note dated August 15, 2023, previously amended May 7, 2024).
- Instrument
- loan
- Principal
- not changed
- Counterparty
- same Investor
- Rate
- not changed
- Maturity
- June 15, 2025 (extended from previous maturity; Note dated August 15, 2023, previously amended May 7, 2024)
- Event
- amendment
Exact text from the filing
Effective May 7, 2025, the Company entered into a Maturity Extension Agreement (the "Extension Agreement") with the same Investor whereby the Investor agreed to extend the maturity date of a previously issued promissory note dated August 15, 2023, which was amended on May 7, 2024 (the "Old Note") to June 15, 2025.
View on SEC.gov
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.95
Propanc Biopharma, Inc. incurred loan of aggregate principal amount of $90,000, for a purchase price of $75,000 with accredited investor at ten percent (10%) per annum maturing June 15, 2025.
- Instrument
- loan
- Principal
- aggregate principal amount of $90,000, for a purchase price of $75,000
- Counterparty
- accredited investor
- Rate
- ten percent (10%) per annum
- Maturity
- June 15, 2025
- Event
- incurrence
Exact text from the filing
Effective May 7, 2025, Propanc Biopharma, Inc. (the "Company") issued a Promissory Note to an accredited investor (the "Investor") in the aggregate principal amount of $90,000 (the "Note"), for a purchase price of $75,000.
View on SEC.gov